Alyeska Investment Group L.P. Has $1.44 Million Stock Holdings in CeriBell, Inc. $CBLL

Key Points

• Alyeska Investment Group L.P. reduced its stake in CeriBell, Inc. by 40%, owning 75,000 shares worth approximately $1.44 million after selling 50,000 shares in the first quarter.
• Several institutional investors acquired new stakes in CeriBell during the fourth quarter, with Northern Trust Corp making the largest investment at approximately $2.66 million.
• Analysts continue to have a positive outlook on CeriBell, with a consensus "Buy" rating and a price target of $32.14, following BTIG Research's initiation of coverage.

Alyeska Investment Group L.P. reduced its position in CeriBell, Inc. (NASDAQ:CBLL - Free Report) by 40.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 75,000 shares of the company's stock after selling 50,000 shares during the period. Alyeska Investment Group L.P. owned approximately 0.21% of CeriBell worth $1,441,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of CBLL. Tower Research Capital LLC TRC acquired a new stake in CeriBell in the fourth quarter valued at $37,000. BNP Paribas Financial Markets acquired a new stake in shares of CeriBell in the 4th quarter worth about $43,000. KLP Kapitalforvaltning AS bought a new stake in shares of CeriBell during the first quarter valued at approximately $36,000. New York State Common Retirement Fund bought a new position in shares of CeriBell in the first quarter worth $67,000. Finally, Wells Fargo & Company MN bought a new position in CeriBell in the 4th quarter valued at about $167,000.

Wall Street Analysts Forecast Growth

Separately, BTIG Research initiated coverage on CeriBell in a report on Tuesday, June 24th. They set a "buy" rating and a $30.00 target price on the stock. Eight analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $32.14.

CeriBell Price Performance

CeriBell stock traded down $0.39 during mid-day trading on Wednesday, hitting $11.47. The company's stock had a trading volume of 143,153 shares, compared to its average volume of 289,264. The stock has a market capitalization of $420.49 million and a P/E ratio of -3.84. CeriBell, Inc. has a twelve month low of $10.01 and a twelve month high of $32.75. The stock's fifty day moving average price is $13.97 and its two-hundred day moving average price is $16.86. The company has a quick ratio of 12.91, a current ratio of 13.31 and a debt-to-equity ratio of 0.11.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.02. The company had revenue of $21.20 million during the quarter, compared to the consensus estimate of $20.52 million. CeriBell had a negative return on equity of 48.42% and a negative net margin of 63.83%. CeriBell has set its FY 2025 guidance at EPS. Research analysts forecast that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Rebecca B. Robertson sold 11,188 shares of the firm's stock in a transaction that occurred on Wednesday, June 18th. The stock was sold at an average price of $17.85, for a total value of $199,705.80. Following the transaction, the director directly owned 10,042 shares of the company's stock, valued at approximately $179,249.70. This trade represents a 52.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Xingjuan Chao sold 25,000 shares of the business's stock in a transaction on Monday, July 7th. The stock was sold at an average price of $17.70, for a total transaction of $442,500.00. Following the completion of the sale, the chief executive officer owned 776,022 shares of the company's stock, valued at $13,735,589.40. The trade was a 3.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 64,499 shares of company stock valued at $1,126,402. Insiders own 20.10% of the company's stock.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.